Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Cyclacel Pharmaceuti (NASDAQ: CYCC)

$4.87 USD $0.00 (0.00%)
Last Price $4.87
Net Change $0 (0%)
Bid $0
Ask Price $0
Open Price $4.85
Previous Close Price $4.87
High Price $4.92
Low Price $4.7
Number of Trades 86
Volume 31,300
Fifty Two Week High $10.9 (2017-04-04)
Fifty Two Week Low $3.05 (2016-11-08)
Average Daily Volume 542,828
Share Outstanding 4,270 Shares
Total Dividend Payout 0.15/yr
Dividend Yield 3.08%
1st Quarter Earnings $ ()
2nd Quarter Earnings $ ()
3nd Quarter Earnings $ ()
4th Quarter Earnings $ ()
PE Ratio $0
EPS Growth $35.71
Recent Earnings $
Annual EPS $-4.84
Last Quarter EPS $
Market Capitalization $0.02B
Insider Shareholders % 0.04%
Annual Revenue $0B
No. Shares Outstanding 4,270
Inst. Shareholder % 21.49%
Annual Net Income $-0.01B
TTM Net Profit Margin $-1453.52
1-Year Return 4.4%
3-Year Return -87.22%
5-Year Return -90.67%
5-Year Revenue Growth 20%
5-Year Earnings Growth -86.98%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 3.08%
Change in EPS YTD 35.709999%
Dividends per Share $0.15
Stock Split Ratio 1-12
Beta 2.96
CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

CYCC News & Stock Updates